This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Reported reason: Other
Product Information
LISDEXAMFETAMINE 40 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $2.6013 per EA under NDC 57664004988. Its NADAC has been published 156 times since Oct 11, 2023.
FDA first approved this application on Aug 25, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
57664004988
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA214484FDA Approved
8/25/2023
TE Code
AB
On Market Since
8/25/2023
Pharmacological Classes
Price Statistics
The NADAC for LISDEXAMFETAMINE 40 MG CAPSULE has been published 156 times since Oct 11, 2023, and over the history we have for it it has declined 21.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6013 per EA |
|---|---|
| All-time high | $6.5053 (Mar 13, 2024) |
| All-time low | $2.6013 (Sep 23, 2026) |
| 52-week high | $3.5182 |
| 52-week low | $2.6013 |
| Median price | $4.0402 |
| Average price | $3.9791 |
| Largest weekly change | +41.6% (Jan 17, 2024) |
| Weeks tracked | 156 |
| Tracking since | Oct 11, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LISDEXAMFETAMINE DIMESYLATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LISDEXAMFETAMINE 40 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LISDEXAMFETAMINE 40 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $2.6013 per EA (NDC 57664004988), effective Sep 30, 2026.
How has the price of LISDEXAMFETAMINE 40 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for LISDEXAMFETAMINE 40 MG CAPSULE has declined 21.9%. It has been tracked across 156 weekly CMS publications since Oct 11, 2023.
What are the highest and lowest recorded NADAC prices for LISDEXAMFETAMINE 40 MG CAPSULE?
Since Oct 11, 2023, the NADAC for LISDEXAMFETAMINE 40 MG CAPSULE has ranged from a low of $2.6013 (Sep 23, 2026) to a high of $6.5053 (Mar 13, 2024), with a median of $4.0402 per EA.
Are there cheaper alternatives to LISDEXAMFETAMINE 40 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LISDEXAMFETAMINE 40 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LISDEXAMFETAMINE 40 MG CAPSULE?
LISDEXAMFETAMINE 40 MG CAPSULE (NDC 57664004988) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.
Is LISDEXAMFETAMINE 40 MG CAPSULE in shortage?
Yes — NDC 57664004988 is currently listed in FDA's drug shortage database (posted Jul 14, 2023). Reported reason: Other.